BiotechTube

Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Placebo: NaCl 0.9%

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dengue Fever

Conditions

Dengue Fever, Dengue Hemorrhagic Fever

Trial Timeline

Oct 5, 2010 → Feb 1, 2013

NCT ID
NCT01134263

About Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Placebo: NaCl 0.9%

Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus + Placebo: NaCl 0.9% is a phase 3 stage product being developed by Sanofi for Dengue Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT01134263. Target conditions include Dengue Fever, Dengue Hemorrhagic Fever.

What happened to similar drugs?

0 of 8 similar drugs in Dengue Fever were approved

Approved (0) Terminated (1) Active (7)
❌CYD Dengue Vaccine + Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed + Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedSanofiPhase 3
🔄Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Placebo: NaCl 0.9%SanofiPhase 3
🔄Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: (NaCl) 0.9% solutionSanofiPhase 3
🔄CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.SanofiPhase 3
🔄Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: Sodium chloride (NaCl) 0.9%SanofiPhase 3
🔄Live, attenuated dengue serotype 1, 2, 3, and 4 virus + Yellow fever vaccine + Measles, mumps, and rubella (MMR) vaccine + Pneumococcal Conjugated Vaccine + Hepatitis A Pediatric Vaccine + Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine + Live, attenuated dengue serotype 1, 2, 3, and 4 virus + Yellow Fever Vaccine + Placebo (NaCl) + Measles, mumps, and rubella vaccine + Pneumococcal Conjugated Vaccine + Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine + Hepatitis A Pediatric VaccineSanofiPhase 3
🔄CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant + Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, RecombinantSanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01134263Phase 3Completed

Competing Products

20 competing products in Dengue Fever

See all competitors
ProductCompanyStageHype Score
V180 + Alhydrogel™ + PlaceboMerckPhase 1
29
Low-dose V180 with low-dose ISCOMATRIX™ adjuvant + Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Medium-dose V180 (non-adjuvanted) + Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with Alhydrogel™ adjuvant + High-dose V180 (non-adjuvanted) + High-dose V180 with low-dose ISCOMATRIX™ adjuvant + High-dose V180 with medium-dose ISCOMATRIX™ adjuvant + Low-dose V180 with high-dose ISCOMATRIX™ adjuvant + Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant + High-dose V180 with high-dose ISCOMATRIX™ adjuvant + PlaceboMerckPhase 1
29
V181 + Butantan - DVMerckPhase 2
35
V181 High-Potency Level + V181 Mid-Potency Level + V181 Low-Potency Level + PlaceboMerckPhase 2
35
EYU688 + PlaceboNovartisPhase 2
42
balapiravir [RO4588161] + placeboRochePhase 1
29
Dengue Tetravalent Vaccine, LiveSanofiPre-clinical
33
CYD Dengue Vaccine (5-dose formulation) + Placebo, NaCl 0.9%SanofiPhase 2
35
Chimeric dengue serotype (1, 2, 3, 4) + Chimeric dengue serotype (1, 2, 3, 4) + Chimeric dengue serotype (1, 2, 3, 4)SanofiPhase 2
35
Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus + NaCl 0.9% + Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed + Meningococcal A+C vaccineSanofiPhase 2
35
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Yellow FeverSanofiPhase 2
35
Tetravalent CYD Dengue Vaccine , 5555 formulation + Tetravalent CYD Dengue Vaccine , 5553 formulation + Tetravalent CYD Dengue Vaccine, 4444 formulationSanofiPhase 2
35
CYD Dengue Vaccine + Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed + Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbedSanofiPhase 3
32
Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus + Placebo: NaCl 0.9%SanofiPhase 3
40
Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: (NaCl) 0.9% solutionSanofiPhase 3
40
CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.SanofiPhase 3
40
CYD dengue vaccine serotypes (1, 2, 3, 4). + Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharideSanofiPhase 2
35
CYD Dengue Vaccine + Placebo (Sodium chloride 0.9%)SanofiPhase 2
35
CYD Dengue Vaccine + Inactivated rabies virus vaccine + PlaceboSanofiPhase 2
35
Live, attenuated, dengue serotype 1, 2, 3, 4 virus + Placebo: Sodium chloride (NaCl) 0.9%SanofiPhase 3
40